XIST
MPARK
Market cap1.28bUSD
Nov 12, Last price
329.50TRY
Name
MLP Saglik Hizmetleri AS
Chart & performance
P/E
11.37
P/S
1.14
EPS
28.99
Div yield, %
—
Shrs. gr., 5y
-1.69%
Rev. gr., 5y
68.85%
Revenues
55.09b
+38.81%
Net income
5.54b
+6.27%
CFO
9.42b
+23.32%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MLP Saglik Hizmetleri AS operates private medical institutions. Its brands include Medical Park, Liv Hospital, VM Medical Park, and Istinye University Hospital. The company was founded by Muharrem Usta and Adem Elbasi in 1993 and is headquartered in Istanbul, Turkey.
Key people
Muharrem Usta
Executive Chairman of the Board, Chief Executive Officer · since 2005
Non-Executive Vice Chairman of the Board, Representing Sullivan B.V. · since 2014
Burcu Oeztuerk
Chief Financial Officer · since 2014
Adem Elbasi
Chief Operations Coordinator · since 2012
Serafettin Demiray
Human Resources Coordinator · since 2024
Strategy and Investor Relations Director · since 2024
Guerkan Caglioglu
Information Systems and Digital Transformation Coordinator · since 2024
Hikmet Cavus
Chief Strategy and Performance Coordinator · since 2013
Muzemmil Hevadpal
Internal Audit Director · since 2024
Hatice Biyikli
Non-Executive Director, Representing Elinor B.V. · since 2014
Haydar Sancak
Non-Executive Director, Representing Sancak Insaat · since 2006
Non-Executive Independent Director · since 2018
Betuel Edin
Non-Executive Independent Director · since 2024
Temel Guezeloglu
Non-Executive Independent Director · since 2024
Legal address
OTAKÇILAR CD.FLATOFİS İSTANBUL NO:78 KAT:3 D BLOK NO:103 EYÜPSULTAN / İSTANBUL
İSTANBUL 34050
TR
İSTANBUL 34050
TR
Headquarters
Otakçılar cad. Flatofis No:78 Kat:3 D Blok No:103 Eyüp
İSTANBUL 34050
TR
İSTANBUL 34050
TR
Previous name
MLP Sağlık Hizmetleri AŞ
Valuation
Title TRY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||